Remove Development Remove Equity Remove Thousand Oaks
article thumbnail

Amgen CFO To Retire

socalTECH

Thousand Oaks-based biotech giant Amgen said today that its CFO, David W. Meline, is planning to retire, serving as CFO through the end of 2019, but will remain at the company through the second quarter of 2020. Meline--who has been Executive Vice President and Chief Financial Officer at Amgen since 2014--will be replaced by Peter H.

article thumbnail

ImmunGene Raises $9M

socalTECH

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amgen Backs Therapeutic Antibody Firm

socalTECH

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer.

article thumbnail

Ceres Raises $20M

socalTECH

Thousand Oaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Ceres has previously raised funds from Warburg Pincus, Soros Private Equity, QuestMark Partners, Oxford BioScience, Oppenheimer, Monsanto, KBC, H&Q, and GIMV.

article thumbnail

Ceres, Novozymes In Biofuels Collaboration

socalTECH

Thousand Oaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Ceres is working on both crops to optimize the amount of sugar which can be used to produce biofuel.

article thumbnail

Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More

Xconomy

. —Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40
article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.